Daxor Corporation (DXR)
NASDAQ: DXR · Real-Time Price · USD
10.05
-0.15 (-1.47%)
Oct 16, 2026, 4:00 PM EDT - Market closed
Daxor Earnings Call Transcripts
Fiscal Year 2026
-
A direct blood volume analysis technology is driving improved patient outcomes and cost savings, with a new portable analyzer and expanded commercial reach. Revenue grew 45% in 2025, supported by strong partnerships, a recent capital raise, and a robust IP portfolio.
Fiscal Year 2024
-
Net assets and revenue grew significantly in 2024, with cash flow break-even achieved in early 2025. Major product launches, expanded clinical adoption, and new contracts position the company for further growth, pending regulatory milestones.